Lisa J T Smits
Overview
Explore the profile of Lisa J T Smits including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Linschoten R, Jansen F, Pauwels R, Smits L, Atsma F, Kievit W, et al.
Dig Dis Sci
. 2024 Apr;
69(6):2165-2174.
PMID: 38594435
Background: In the pragmatic open-label randomised controlled non-inferiority LADI trial we showed that increasing adalimumab (ADA) dose intervals was non-inferior to conventional dosing for persistent flares in patients with Crohn's...
2.
Jansen F, van Linschoten R, Kievit W, Smits L, Pauwels R, de Jong D, et al.
J Crohns Colitis
. 2023 Jun;
17(11):1771-1780.
PMID: 37310877
Background And Aims: We aimed to assess cost-effectiveness of increasing adalimumab dose intervals compared to the conventional dosing interval in patients with Crohn's disease [CD] in stable clinical and biochemical...
3.
Jansen F, Smits L, Thomas P, de Jong D, Kreijne J, van Dop W, et al.
Dig Dis Sci
. 2023 May;
68(7):2936-2945.
PMID: 37131100
Background: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs...
4.
van Linschoten R, Jansen F, Pauwels R, Smits L, Atsma F, Kievit W, et al.
Lancet Gastroenterol Hepatol
. 2023 Feb;
8(4):343-355.
PMID: 36736339
Background: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab...
5.
Thomas P, Smits L, Te Groen M, West R, Russel M, Jansen J, et al.
Eur J Gastroenterol Hepatol
. 2022 Jan;
34(5):488-495.
PMID: 34974465
Background: Limited data are available on biological therapy de-escalation after prior escalation in inflammatory bowel disease (IBD) patients. This study aimed to assess the frequency and success rate of de-escalation...
6.
Mahmmod S, Schultheiss J, van Bodegraven A, Dijkstra G, Gilissen L, Hoentjen F, et al.
Inflamm Bowel Dis
. 2021 Feb;
27(12):1954-1962.
PMID: 33538298
Background: Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are "reverse switched" to treatment with the originator....
7.
Smits L, van Esch A, Derikx L, Boshuizen R, de Jong D, Drenth J, et al.
Inflamm Bowel Dis
. 2018 Jun;
25(1):172-179.
PMID: 29947795
Background: The infliximab biosimilar has entered daily inflammatory bowel disease (IBD) practice. However, real-life outcomes beyond 1 year after switching are scarce. We aimed to investigate the long-term drug survival,...
8.
Urbano P, Aguirre-Gamboa R, Ashikov A, van Heeswijk B, Krippner-Heidenreich A, Tijssen H, et al.
J Allergy Clin Immunol
. 2017 Dec;
142(2):517-529.
PMID: 29248493
Background: Anti-TNF inhibitors successfully improve the quality of life of patients with inflammatory disease. Unfortunately, not all patients respond to anti-TNF therapy, and some patients show paradoxical immune side effects,...
9.
Smits L, Grelack A, Derikx L, de Jong D, van Esch A, Boshuizen R, et al.
Dig Dis Sci
. 2017 Jul;
62(11):3117-3122.
PMID: 28667429
Background: Limited data are available on long-term clinical outcomes regarding the switch from Remicade to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) patients. Aims: To investigate long-term efficacy,...
10.
Derikx L, Smits L, van Vliet S, Dekker E, Aalfs C, van Kouwen M, et al.
Clin Gastroenterol Hepatol
. 2016 Aug;
15(3):454-458.e1.
PMID: 27521512
Lynch syndrome and inflammatory bowel diseases (IBD) are associated with an increased risk of colorectal cancer (CRC). However, it is not clear whether the risk of CRC is even higher...